JP2017113028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017113028A5 JP2017113028A5 JP2017040585A JP2017040585A JP2017113028A5 JP 2017113028 A5 JP2017113028 A5 JP 2017113028A5 JP 2017040585 A JP2017040585 A JP 2017040585A JP 2017040585 A JP2017040585 A JP 2017040585A JP 2017113028 A5 JP2017113028 A5 JP 2017113028A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- seq
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 101100440311 Homo sapiens C5 gene Proteins 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019098449A JP7450344B2 (ja) | 2014-03-07 | 2019-05-27 | 向上した薬物動態を有する抗ｃ５抗体 |
| JP2024011008A JP2024038502A (ja) | 2014-03-07 | 2024-01-29 | 向上した薬物動態を有する抗ｃ５抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461949932P | 2014-03-07 | 2014-03-07 | |
| US61/949,932 | 2014-03-07 | ||
| JP2016555463A JP6112469B1 (ja) | 2014-03-07 | 2015-03-06 | 向上した薬物動態を有する抗ｃ５抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555463A Division JP6112469B1 (ja) | 2014-03-07 | 2015-03-06 | 向上した薬物動態を有する抗ｃ５抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019098449A Division JP7450344B2 (ja) | 2014-03-07 | 2019-05-27 | 向上した薬物動態を有する抗ｃ５抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017113028A JP2017113028A (ja) | 2017-06-29 |
| JP2017113028A5 true JP2017113028A5 (enExample) | 2018-03-29 |
| JP6894265B2 JP6894265B2 (ja) | 2021-06-30 |
Family
ID=52684742
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555463A Active JP6112469B1 (ja) | 2014-03-07 | 2015-03-06 | 向上した薬物動態を有する抗ｃ５抗体 |
| JP2017040585A Active JP6894265B2 (ja) | 2014-03-07 | 2017-03-03 | 向上した薬物動態を有する抗ｃ５抗体 |
| JP2019098449A Active JP7450344B2 (ja) | 2014-03-07 | 2019-05-27 | 向上した薬物動態を有する抗ｃ５抗体 |
| JP2020173023A Pending JP2021036870A (ja) | 2014-03-07 | 2020-10-14 | 向上した薬物動態を有する抗ｃ５抗体 |
| JP2024011008A Pending JP2024038502A (ja) | 2014-03-07 | 2024-01-29 | 向上した薬物動態を有する抗ｃ５抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555463A Active JP6112469B1 (ja) | 2014-03-07 | 2015-03-06 | 向上した薬物動態を有する抗ｃ５抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019098449A Active JP7450344B2 (ja) | 2014-03-07 | 2019-05-27 | 向上した薬物動態を有する抗ｃ５抗体 |
| JP2020173023A Pending JP2021036870A (ja) | 2014-03-07 | 2020-10-14 | 向上した薬物動態を有する抗ｃ５抗体 |
| JP2024011008A Pending JP2024038502A (ja) | 2014-03-07 | 2024-01-29 | 向上した薬物動態を有する抗ｃ５抗体 |
Country Status (28)
| Country | Link |
|---|---|
| US (11) | US9079949B1 (enExample) |
| EP (3) | EP3594235A1 (enExample) |
| JP (5) | JP6112469B1 (enExample) |
| KR (4) | KR101796886B1 (enExample) |
| CN (2) | CN113416254B (enExample) |
| AR (1) | AR099698A1 (enExample) |
| AU (4) | AU2015226977B2 (enExample) |
| BR (1) | BR112016020454B1 (enExample) |
| CA (2) | CA3166772A1 (enExample) |
| CY (1) | CY1118018T1 (enExample) |
| DK (2) | DK2970455T3 (enExample) |
| EA (2) | EA035025B1 (enExample) |
| ES (2) | ES2749978T3 (enExample) |
| HR (1) | HRP20161146T1 (enExample) |
| HU (2) | HUE030944T2 (enExample) |
| IL (4) | IL296502A (enExample) |
| LT (1) | LT2970455T (enExample) |
| MA (2) | MA38859B1 (enExample) |
| ME (1) | ME02629B (enExample) |
| MX (2) | MX368909B (enExample) |
| NZ (2) | NZ711451A (enExample) |
| PL (2) | PL2970455T3 (enExample) |
| PT (2) | PT2970455T (enExample) |
| RS (1) | RS55386B1 (enExample) |
| SI (2) | SI2970455T1 (enExample) |
| SM (1) | SMT201600366B (enExample) |
| TW (4) | TW202446794A (enExample) |
| WO (1) | WO2015134894A1 (enExample) |
Families Citing this family (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2006381B1 (en) | 2006-03-31 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Method for controlling blood pharmacokinetics of antibodies |
| CA2700701C (en) | 2007-09-26 | 2020-12-29 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| NZ717429A (en) | 2008-04-11 | 2018-07-27 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| CN112812184A (zh) | 2011-02-25 | 2021-05-18 | 中外制药株式会社 | FcγRIIb特异性Fc抗体 |
| TWI687441B (zh) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | 異源二聚化多胜肽 |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| EP2787081A4 (en) | 2011-11-30 | 2015-10-07 | Chugai Pharmaceutical Co Ltd | PHARMACEUTICAL CARRIER IN CELLS FOR THE FORMATION OF AN IMMUNOMOPLEX |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| JP6276202B2 (ja) | 2012-02-20 | 2018-02-07 | スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） | ヒト補体ｃ５に結合するポリペプチド |
| CN103382223B (zh) * | 2012-04-01 | 2015-06-10 | 上海益杰生物技术有限公司 | 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽 |
| EP3721900A1 (en) | 2012-08-24 | 2020-10-14 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc region variant |
| KR102249779B1 (ko) | 2012-12-27 | 2021-05-07 | 추가이 세이야쿠 가부시키가이샤 | 헤테로이량화 폴리펩티드 |
| KR102318483B1 (ko) | 2013-04-02 | 2021-10-27 | 추가이 세이야쿠 가부시키가이샤 | Ｆｃ영역 개변체 |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| CA2964857A1 (en) * | 2014-10-20 | 2016-04-28 | Nestec S.A. | Methods for prediction of anti-tnf alpha drug levels and autoantibody formation |
| WO2016094834A2 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | A method for treating a complement mediated disorder caused by an infectious agent in a patient |
| TWI617580B (zh) | 2014-12-19 | 2018-03-11 | 中外製藥股份有限公司 | 抗ｃ５抗體及使用方法 |
| KR102650420B1 (ko) | 2014-12-19 | 2024-03-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| WO2016117346A1 (en) * | 2015-01-22 | 2016-07-28 | Chugai Seiyaku Kabushiki Kaisha | A combination of two or more anti-c5 antibodies and methods of use |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| EP4269440A3 (en) | 2015-02-27 | 2024-02-28 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
| EP3274359B1 (en) | 2015-03-23 | 2022-11-02 | Alexion Pharmaceuticals, Inc. | Virus filtration |
| US20190135903A1 (en) | 2015-03-31 | 2019-05-09 | Alexion Pharmaceuticals, Inc. | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients |
| US20180311299A1 (en) | 2015-05-01 | 2018-11-01 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
| US11207465B2 (en) | 2015-06-04 | 2021-12-28 | West Pharma. Services Il. Ltd. | Cartridge insertion for drug delivery device |
| EP4462121A3 (en) | 2015-09-11 | 2025-01-22 | Alexion Pharmaceuticals, Inc. | Recombinant glycosylated eculizumab and eculizumab variants |
| CA2997745A1 (en) | 2015-09-14 | 2017-03-23 | Children's Hospital Medical Center | Methods and compositions for treatment of gaucher disease via modulation of c5a receptor |
| HK1259307A1 (zh) | 2015-10-07 | 2019-11-29 | 阿佩利斯制药有限公司 | 给药方案 |
| JP2018530574A (ja) | 2015-10-07 | 2018-10-18 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の加齢黄斑変性を治療する方法 |
| US20180311345A1 (en) | 2015-10-30 | 2018-11-01 | Alexion Pharmaceuticals, Inc. | A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy |
| TWI747936B (zh) * | 2015-12-18 | 2021-12-01 | 日商中外製藥股份有限公司 | 抗ｃ５抗體及使用方法 |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| EP3395835B1 (en) * | 2015-12-25 | 2021-02-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
| US20190023775A1 (en) | 2016-01-11 | 2019-01-24 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| MA53248A (fr) * | 2016-01-25 | 2022-02-16 | Takeda Pharmaceuticals Co | Anticorps anti-c5 à commutation ph améliorée |
| PL234632B1 (pl) * | 2016-03-02 | 2020-03-31 | Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk | Przeciwciała oddziałujące z komórkami psich chłoniaków typu B i ich zastosowania |
| EP3449940B1 (en) | 2016-04-28 | 2025-11-19 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
| CN109475630A (zh) | 2016-05-27 | 2019-03-15 | 瑞颂医药公司 | 治疗难治性全身型重症肌无力的方法 |
| RU2018146778A (ru) | 2016-06-07 | 2020-07-09 | Новартис Аг | Режим дозирования антитела к c5 |
| EP4374922A3 (en) | 2016-06-14 | 2024-08-28 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| EA201990018A1 (ru) * | 2016-06-17 | 2019-08-30 | Чугаи Сейяку Кабусики Кайся | Антитела к с5 и способы их применения |
| TW202300168A (zh) | 2016-08-05 | 2023-01-01 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
| WO2018071624A1 (en) | 2016-10-12 | 2018-04-19 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
| ES2848206T3 (es) | 2016-10-19 | 2021-08-05 | Alexion Pharma Inc | Un método de cuantificar C5 sin unir en una muestra |
| EP3532845A1 (en) | 2016-10-27 | 2019-09-04 | Alexion Pharmaceuticals, Inc. | Assay for c5b-9 deposition in complement-associated disorders |
| US20190330319A1 (en) * | 2016-12-16 | 2019-10-31 | Samsung Bioepis Co., Ltd | Stable aqueous anti-c5 antibody composition |
| JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
| KR101949891B1 (ko) * | 2017-01-31 | 2019-02-19 | 추가이 세이야쿠 가부시키가이샤 | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 |
| CA3055541A1 (en) * | 2017-03-06 | 2018-09-13 | The Trustees Of The University Of Pennsylvania | Anti-c5 antibodies and uses thereof |
| US11112411B2 (en) | 2017-03-31 | 2021-09-07 | Alexion Pharmaceuticals, Inc. | Method for simultaneous quantification of ALXN1210 and eculizumab in human serum or urine |
| AU2018249627B2 (en) | 2017-04-07 | 2025-04-03 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| EP3612561A1 (en) | 2017-04-19 | 2020-02-26 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
| EP3615564A1 (en) | 2017-04-24 | 2020-03-04 | Alexion Pharmaceuticals, Inc. | Antibody immune cell inhibitor fusion proteins |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| MX2019014316A (es) | 2017-05-30 | 2020-01-27 | Chong Kun Dang Pharmaceutical Corp | Un nuevo anticuerpo anti-c-met y uso del mismo. |
| KR20250068795A (ko) | 2017-07-11 | 2025-05-16 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질 |
| PT3658184T (pt) | 2017-07-27 | 2023-11-29 | Alexion Pharma Inc | Formulações de anticorpo anti-c5 de elevada concentração |
| US20200262897A1 (en) | 2017-10-04 | 2020-08-20 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis |
| BR112020008182A2 (pt) | 2017-10-26 | 2020-10-27 | Alexion Pharmaceuticals, Inc. | dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua) |
| BR112020008393A2 (pt) | 2017-11-01 | 2020-11-03 | Chugai Seiyaku Kabushiki Kaisha | variante e isoforma de anticorpos com atividade biológica reduzida |
| CN111556895B (zh) | 2017-11-14 | 2024-09-13 | 中外制药株式会社 | 抗-c1s抗体及使用方法 |
| KR20200095485A (ko) * | 2017-12-04 | 2020-08-10 | 라 파마슈티컬스 인코포레이티드 | 보체 활성의 조절인자 |
| SG11202004662RA (en) | 2017-12-13 | 2020-06-29 | Regeneron Pharma | Anti-c5 antibody combinations and uses thereof |
| MA51162A (fr) | 2017-12-15 | 2020-10-21 | Apellis Pharmaceuticals Inc | Schémas posologiques et compositions et procédés associés |
| CN111683703B (zh) | 2017-12-22 | 2022-11-18 | 西氏医药包装(以色列)有限公司 | 适用于不同尺寸的药筒的注射器 |
| WO2019143761A1 (en) * | 2018-01-17 | 2019-07-25 | Children's Hospital Medical Center | Compositions and methods for treatment of hunter's syndrome |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| JP7520725B2 (ja) * | 2018-05-31 | 2024-07-23 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における発作性夜間ヘモグロビン尿症（ｐｎｈ）の治療のための抗ｃ５抗体の用量および投与 |
| US12460012B2 (en) | 2018-06-04 | 2025-11-04 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients |
| US20210238268A1 (en) * | 2018-06-19 | 2021-08-05 | Atarga, Llc | Antibody molecules to complement component 5 and uses thereof |
| EP3814373A1 (en) * | 2018-06-28 | 2021-05-05 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-c5 antibodies |
| SG10202106830VA (en) | 2018-08-10 | 2021-08-30 | Chugai Pharmaceutical Co Ltd | Anti-cd137 antigen-binding molecule and utilization thereof |
| JP7538113B2 (ja) | 2018-08-20 | 2024-08-21 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 補体ｄ因子の医学的障害の治療のための医薬化合物 |
| CN113038967A (zh) * | 2018-09-06 | 2021-06-25 | 宾夕法尼亚大学理事会 | 人源化抗c5抗体及其用途 |
| WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| US20220056115A1 (en) | 2018-09-17 | 2022-02-24 | Kyoto University | Administration of an anti-c5 agent for treatment of hepatic injury or failure |
| US20200095307A1 (en) | 2018-09-21 | 2020-03-26 | Alexion Pharmaceuticals, Inc. | Compositions and methods for the treatment of neuromyelitis optica |
| EP3863657A4 (en) * | 2018-10-12 | 2022-07-20 | Trican Biotechnology Co., Ltd | BIFUNCTIONAL FUSION PROTEINS AND USES THEREOF |
| US12240893B2 (en) | 2018-10-30 | 2025-03-04 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) |
| WO2020092546A1 (en) | 2018-10-30 | 2020-05-07 | Alexion Pharmaceuticals, Inc. | Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions |
| US20220002393A1 (en) | 2018-11-20 | 2022-01-06 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis in pediatric patients |
| JP7511566B2 (ja) | 2019-01-25 | 2024-07-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与 |
| US11642470B2 (en) * | 2019-02-11 | 2023-05-09 | West Pharma. Services IL, Ltd. | Anti-C5 antibody dispensing injector and method of injection |
| CN113614106A (zh) * | 2019-02-14 | 2021-11-05 | 亚力兄制药公司 | 抗c5抗体用于治疗全身型重症肌无力的剂量和施用 |
| WO2020219922A1 (en) * | 2019-04-24 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof |
| US12473353B2 (en) | 2019-05-15 | 2025-11-18 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule, a pharmaceutical composition, and a method |
| WO2020242849A1 (en) | 2019-05-24 | 2020-12-03 | Alexion Pharmaceuticals, Inc. | Methods of treating vitiligo using an anti-c5 antibody |
| EP3980047B1 (en) * | 2019-06-04 | 2024-02-14 | RA Pharmaceuticals, Inc. | Inflammatory disease treatment with complement inhibitors |
| US20220259305A1 (en) | 2019-08-05 | 2022-08-18 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis with eculizumab |
| US20220356234A1 (en) | 2019-10-02 | 2022-11-10 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
| WO2021091937A1 (en) | 2019-11-08 | 2021-05-14 | Alexion Pharmaceuticals, Inc. | High concentration anti-c5 antibody formulations |
| CA3161271A1 (en) * | 2019-12-09 | 2021-06-17 | Alexion Pharmaceuticals, Inc. | Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder |
| EP4081805A1 (en) * | 2019-12-23 | 2022-11-02 | Alexion Pharmaceuticals, Inc. | Methods of treating pregnancy-associated atypical hemolytic uremic syndrome using an anti-c5 antibody |
| JP2023515073A (ja) | 2020-02-20 | 2023-04-12 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体因子ｄ媒介障害の処置用のヘテロアリール化合物 |
| CN116406287A (zh) | 2020-04-16 | 2023-07-07 | 巴黎公共医疗救助机构 | 治疗由病毒引起的补体介导的障碍的方法 |
| JP2023523790A (ja) | 2020-04-30 | 2023-06-07 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 補体因子Ｂ（ＣＦＢ）ｉＲＮＡ組成物およびその使用方法 |
| CA3178589A1 (en) | 2020-05-12 | 2021-11-18 | Mingjun Huang | Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria |
| JP2023525581A (ja) | 2020-05-15 | 2023-06-16 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体の活性化を検出するための細胞外小胞の使用方法、並びに補体性疾患の処置を評価及び／又は監視するためのその使用 |
| CN113754763B (zh) * | 2020-06-05 | 2024-03-08 | 天辰生物医药(苏州)有限公司 | 分离的抗原结合蛋白及其用途 |
| CA3173011A1 (en) * | 2020-06-24 | 2021-12-30 | Alexion Pharmaceuticals, Inc. | Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions |
| WO2021263056A1 (en) * | 2020-06-25 | 2021-12-30 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of amyotrophic lateral sclerosis |
| EP4295905A1 (en) | 2020-07-09 | 2023-12-27 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| MX2023001702A (es) | 2020-08-13 | 2023-03-09 | Alexion Pharma Inc | Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la microangiopatia trombotica asociada al trasplante de celulas madre hematopoyeticas (hsct-tma). |
| CN116261569A (zh) | 2020-09-21 | 2023-06-13 | 阿雷克森制药公司 | 用于治疗包括狼疮性肾炎（LN）和/或IgA肾病（IgAN）的C5介导的肾小球肾炎（GN）的抗C5抗体的剂量和施用 |
| JP7787164B2 (ja) | 2020-09-23 | 2025-12-16 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体媒介性障害の治療のための医薬化合物 |
| CA3196434A1 (en) | 2020-10-23 | 2022-04-28 | Krista K. JOHNSON | Methods of treating patients having complement disorders using anti-c5 antibodies |
| CN117043190A (zh) * | 2020-12-07 | 2023-11-10 | 因外泰克斯公司 | 延长治疗剂在家畜动物中的半衰期的组合物和使用方法 |
| CN114149501B (zh) * | 2020-12-11 | 2023-05-26 | 天士力生物医药股份有限公司 | 抗c5抗体及其应用 |
| CN117042798A (zh) * | 2020-12-25 | 2023-11-10 | 宾夕法尼亚大学理事会 | 人源化抗-c5抗体和因子h融合蛋白及其用途 |
| AU2022210283A1 (en) | 2021-01-22 | 2023-08-03 | Alexion Pharmaceuticals, Inc. | Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody |
| EP4348263A1 (en) | 2021-05-28 | 2024-04-10 | Alexion Pharmaceuticals, Inc. | Methods for detecting cm-tma biomarkers |
| WO2022265915A1 (en) | 2021-06-14 | 2022-12-22 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating dermatomyositis (dm) |
| EP4370547A1 (en) | 2021-07-14 | 2024-05-22 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis |
| WO2023023220A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor |
| CN118234749A (zh) | 2021-09-17 | 2024-06-21 | 诺华股份有限公司 | 用于预防异种移植中的移植物排斥的方法 |
| IL312399A (en) | 2021-10-29 | 2024-06-01 | Alnylam Pharmaceuticals Inc | Complement factor B (CFB) iRNA compositions and methods of using them |
| MX2024005285A (es) * | 2021-11-01 | 2024-09-18 | Ipc Res Llc | Administracion de proteinas de union a c5. |
| WO2024054436A1 (en) | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
| TW202426048A (zh) | 2022-09-06 | 2024-07-01 | 美商阿雷希昂製藥公司 | 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與 |
| TW202423479A (zh) | 2022-09-28 | 2024-06-16 | 美商阿雷希昂製藥公司 | 用於預防或最小化患有慢性腎病的患者中的心臟手術相關急性腎損傷（csa-aki）和/或隨後的主要不良腎事件（make）的抗c5抗體之劑量及投與 |
| WO2024238421A1 (en) | 2023-05-12 | 2024-11-21 | Alexion Pharmaceuticals, Inc. | Use of biomarkers for the identification and treatment of complement-mediated disorders |
| WO2024238422A1 (en) | 2023-05-12 | 2024-11-21 | Alexion Pharmaceuticals, Inc. | Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles |
| CN116712390B (zh) * | 2023-08-04 | 2023-11-14 | 上海览屹医药科技有限公司 | 一种高浓度高稳定性的抗体制剂及其制备方法 |
| WO2025045250A1 (en) | 2023-09-03 | 2025-03-06 | Kira Pharmaceuticals (Us) Llc | Anti-human factor d antibody constructs and uses thereof |
| WO2025166118A1 (en) | 2024-02-02 | 2025-08-07 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan) |
| WO2025199107A1 (en) | 2024-03-19 | 2025-09-25 | Alexion Pharmaceuticals, Inc. | Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor |
| WO2025221479A1 (en) | 2024-04-16 | 2025-10-23 | Alexion Pharmaceuticals, Inc. | Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| IL79289A (en) | 1985-07-05 | 1992-01-15 | Whitehead Biomedical Inst | Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| DE3785967T2 (de) * | 1986-04-28 | 1993-12-02 | Cetus Corp | Monoklonale Antikörper gegen C5A und DES-ARG74-C5A, ihre Herstellung und ihre Verwendung. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| EP0378576B1 (en) | 1987-09-11 | 1995-01-18 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
| JP2914692B2 (ja) | 1987-12-11 | 1999-07-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 内皮細胞の遺伝子修飾 |
| EP0400047B1 (en) | 1988-02-05 | 1997-04-23 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| DE69128893T2 (de) | 1990-10-31 | 1998-09-10 | Brigham & Womens Hospital | Genetische veränderung von endothelzellen |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| GB9026191D0 (en) | 1990-12-01 | 1991-01-16 | Harris Pharma Ltd | Breath actuated dispensing device |
| AU2238292A (en) | 1991-06-14 | 1993-01-12 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| AU672992B2 (en) | 1992-07-23 | 1996-10-24 | Minnesota Mining And Manufacturing Company | Shaped abrasive particles and method of making same |
| ATE452975T1 (de) | 1992-08-21 | 2010-01-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| ATE204325T1 (de) | 1993-04-29 | 2001-09-15 | Unilever Nv | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| IT1265573B1 (it) | 1993-09-17 | 1996-11-22 | Zanussi Grandi Impianti Spa | Forno di cottura di alimenti con porta perfezionata |
| US5308341A (en) | 1993-09-28 | 1994-05-03 | Becton, Dickinson And Company | Method of testing the dose accuracy of a medication delivery device |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| JPH10501519A (ja) | 1994-03-07 | 1998-02-10 | インヘイル・セラピューティック・システムズ | インシュリンを肺に送給できる方法および組成物 |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO1997042217A1 (en) | 1996-05-06 | 1997-11-13 | The Uab Research Foundation | Radiolabeled fusion toxins for cancer therapy |
| US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| GB9626960D0 (en) | 1996-12-27 | 1997-02-12 | Glaxo Group Ltd | Valve for aerosol container |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO1998047531A2 (en) | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy |
| US5954047A (en) | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| CA2369262A1 (en) | 1999-04-13 | 2000-10-19 | Sudha Nagarajan | Pulmonary administration of dry powder formulations for treating infertility |
| WO2000061178A1 (en) | 1999-04-13 | 2000-10-19 | Inhale Therapeutics Systems, Inc. | Pulmonary administration of dry powder formulations for treating infertility |
| US6192891B1 (en) | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
| GB9910975D0 (en) | 1999-05-13 | 1999-07-14 | Univ Strathclyde | Rapid dehydration of proteins |
| US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| AU2001271417B2 (en) | 2000-08-30 | 2006-10-05 | Johns Hopkins University | Devices for intraocular drug delivery |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| BRPI0211953B8 (pt) * | 2001-08-17 | 2021-05-25 | Genentech Inc | anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro |
| AU2002333554C1 (en) | 2001-09-12 | 2008-12-11 | Becton, Dickinson And Company | Microneedle-based pen device for drug delivery and method for using same |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| US20060141456A1 (en) | 2002-06-12 | 2006-06-29 | Cynthia Edwards | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US20040102469A1 (en) | 2002-09-13 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for reducing the mortality rate |
| GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
| KR100980065B1 (ko) | 2002-09-27 | 2010-09-03 | 젠코어 인코포레이티드 | 최적화된 Ｆｃ 변이체 및 그의 제조 방법 |
| FR2849436B1 (fr) | 2002-12-27 | 2007-01-05 | Patrick Frayssinet | Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro |
| WO2004073551A2 (en) | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
| JP2007500508A (ja) | 2003-07-29 | 2007-01-18 | モルフォテック、インク． | 抗体とエフェクター機能が増強された遺伝子組み換え抗体を作成する方法 |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| GB0416328D0 (en) | 2004-07-21 | 2004-08-25 | Univ Cardiff | Use of dry powder compositions for pulmonary delivery |
| US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP2314618A3 (en) | 2004-11-12 | 2011-10-19 | Xencor Inc. | Fc variants with altered binding to FcRn |
| US20060234303A1 (en) | 2005-03-03 | 2006-10-19 | Xencor, Inc. | Methods for the design of libraries of protein variants |
| AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
| DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
| JP5405122B2 (ja) | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
| EP1988882B1 (en) | 2006-03-02 | 2014-12-17 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| CA3022097C (en) * | 2006-03-15 | 2020-10-27 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| EP2006381B1 (en) | 2006-03-31 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Method for controlling blood pharmacokinetics of antibodies |
| US8037880B2 (en) | 2006-04-07 | 2011-10-18 | The University Of Western Ontario | Dry powder inhaler |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| WO2008048545A2 (en) | 2006-10-16 | 2008-04-24 | Medimmune, Llc. | Molecules with reduced half-lives, compositions and uses thereof |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| EP2173380A4 (en) | 2007-07-13 | 2011-08-31 | Abbott Biotech Ltd | METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER |
| CA2700701C (en) | 2007-09-26 | 2020-12-29 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| KR101616758B1 (ko) | 2007-12-26 | 2016-04-29 | 젠코어 인코포레이티드 | ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체 |
| NZ717429A (en) | 2008-04-11 | 2018-07-27 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| CN110317272A (zh) | 2008-10-14 | 2019-10-11 | 霍夫曼-拉罗奇有限公司 | 免疫球蛋白变体及其用途 |
| AU2009313203B2 (en) * | 2008-11-10 | 2015-08-27 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| EP2373689A1 (en) * | 2008-12-12 | 2011-10-12 | MedImmune, LLC | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
| NZ597259A (en) * | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| WO2011057158A1 (en) * | 2009-11-05 | 2011-05-12 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| WO2011111007A2 (en) * | 2010-03-11 | 2011-09-15 | Rinat Neuroscience Corporation | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| WO2011137362A1 (en) | 2010-04-30 | 2011-11-03 | Rother Russell P | Antibodies having reduced immunogenicity in a human |
| EP2824111B1 (en) * | 2010-04-30 | 2017-03-22 | Alexion Pharmaceuticals, Inc. | Anti-C5A Antibodies and Methods for Using the Antibodies |
| CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| WO2012088247A2 (en) * | 2010-12-22 | 2012-06-28 | Medimmune, Llc | Anti-c5/c5a/c5adesr antibodies and fragments |
| DK2698431T3 (da) | 2011-03-30 | 2020-11-30 | Chugai Pharmaceutical Co Ltd | Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| CA2871934C (en) * | 2012-04-30 | 2023-06-13 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| US20190135903A1 (en) | 2015-03-31 | 2019-05-09 | Alexion Pharmaceuticals, Inc. | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients |
| US20180311299A1 (en) | 2015-05-01 | 2018-11-01 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
| US20180311345A1 (en) | 2015-10-30 | 2018-11-01 | Alexion Pharmaceuticals, Inc. | A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy |
| EP4374922A3 (en) * | 2016-06-14 | 2024-08-28 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| WO2018071624A1 (en) | 2016-10-12 | 2018-04-19 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
-
2014
- 2014-09-11 NZ NZ711451A patent/NZ711451A/en unknown
- 2014-09-11 NZ NZ631007A patent/NZ631007A/en unknown
-
2015
- 2015-03-06 DK DK15710396.1T patent/DK2970455T3/en active
- 2015-03-06 DK DK16177656.2T patent/DK3095795T3/da active
- 2015-03-06 KR KR1020167027411A patent/KR101796886B1/ko active Active
- 2015-03-06 EP EP19176561.9A patent/EP3594235A1/en active Pending
- 2015-03-06 PL PL15710396T patent/PL2970455T3/pl unknown
- 2015-03-06 SI SI201530009A patent/SI2970455T1/sl unknown
- 2015-03-06 TW TW113129415A patent/TW202446794A/zh unknown
- 2015-03-06 LT LTEP15710396.1T patent/LT2970455T/lt unknown
- 2015-03-06 HR HRP20161146TT patent/HRP20161146T1/hr unknown
- 2015-03-06 EA EA201691764A patent/EA035025B1/ru unknown
- 2015-03-06 TW TW108122663A patent/TWI708785B/zh active
- 2015-03-06 TW TW104107187A patent/TWI667256B/zh active
- 2015-03-06 BR BR112016020454-9A patent/BR112016020454B1/pt active IP Right Grant
- 2015-03-06 KR KR1020237018254A patent/KR20230082690A/ko active Pending
- 2015-03-06 WO PCT/US2015/019225 patent/WO2015134894A1/en not_active Ceased
- 2015-03-06 MA MA38859A patent/MA38859B1/fr unknown
- 2015-03-06 ES ES16177656T patent/ES2749978T3/es active Active
- 2015-03-06 TW TW109133882A patent/TWI845769B/zh active
- 2015-03-06 EA EA202090275A patent/EA202090275A3/ru unknown
- 2015-03-06 KR KR1020217011897A patent/KR102539636B1/ko active Active
- 2015-03-06 JP JP2016555463A patent/JP6112469B1/ja active Active
- 2015-03-06 CN CN202110517494.0A patent/CN113416254B/zh active Active
- 2015-03-06 KR KR1020177032026A patent/KR102304136B1/ko active Active
- 2015-03-06 CN CN201580012081.XA patent/CN106459189B/zh active Active
- 2015-03-06 CA CA3166772A patent/CA3166772A1/en active Pending
- 2015-03-06 RS RS20160996A patent/RS55386B1/sr unknown
- 2015-03-06 HU HUE15710396A patent/HUE030944T2/en unknown
- 2015-03-06 HU HUE16177656A patent/HUE046091T2/hu unknown
- 2015-03-06 AR ARP150100697A patent/AR099698A1/es active IP Right Grant
- 2015-03-06 MX MX2016011628A patent/MX368909B/es active IP Right Grant
- 2015-03-06 CA CA2942165A patent/CA2942165C/en active Active
- 2015-03-06 MA MA050373A patent/MA50373A/fr unknown
- 2015-03-06 PL PL16177656T patent/PL3095795T3/pl unknown
- 2015-03-06 ES ES15710396.1T patent/ES2589230T3/es active Active
- 2015-03-06 PT PT157103961T patent/PT2970455T/pt unknown
- 2015-03-06 PT PT161776562T patent/PT3095795T/pt unknown
- 2015-03-06 ME MEP-2016-264A patent/ME02629B/me unknown
- 2015-03-06 US US14/641,026 patent/US9079949B1/en active Active
- 2015-03-06 AU AU2015226977A patent/AU2015226977B2/en active Active
- 2015-03-06 IL IL296502A patent/IL296502A/en unknown
- 2015-03-06 EP EP15710396.1A patent/EP2970455B1/en active Active
- 2015-03-06 EP EP16177656.2A patent/EP3095795B1/en active Active
- 2015-03-06 SI SI201530940T patent/SI3095795T1/sl unknown
- 2015-06-01 US US14/727,313 patent/US9107861B1/en active Active
- 2015-07-01 US US14/789,329 patent/US9206251B2/en active Active
- 2015-10-27 US US14/923,879 patent/US9371377B2/en active Active
-
2016
- 2016-05-20 US US15/160,364 patent/US9663574B2/en active Active
- 2016-08-17 IL IL247331A patent/IL247331B/en active IP Right Grant
- 2016-09-07 MX MX2019012455A patent/MX2019012455A/es unknown
- 2016-09-16 CY CY20161100922T patent/CY1118018T1/el unknown
- 2016-10-12 SM SM201600366T patent/SMT201600366B/it unknown
-
2017
- 2017-03-03 JP JP2017040585A patent/JP6894265B2/ja active Active
- 2017-04-20 US US15/492,622 patent/US9803007B1/en active Active
- 2017-09-19 US US15/708,658 patent/US10227400B2/en active Active
-
2019
- 2019-01-14 US US16/246,842 patent/US10584164B2/en active Active
- 2019-05-27 JP JP2019098449A patent/JP7450344B2/ja active Active
- 2019-09-24 AU AU2019236617A patent/AU2019236617B2/en active Active
-
2020
- 2020-01-23 US US16/750,173 patent/US11434280B2/en active Active
- 2020-03-17 IL IL273337A patent/IL273337B/en unknown
- 2020-10-14 JP JP2020173023A patent/JP2021036870A/ja active Pending
- 2020-11-16 AU AU2020267324A patent/AU2020267324B2/en active Active
-
2021
- 2021-11-15 IL IL288139A patent/IL288139A/en unknown
-
2023
- 2023-07-07 US US18/219,138 patent/US20240141024A1/en active Pending
-
2024
- 2024-01-29 JP JP2024011008A patent/JP2024038502A/ja active Pending
- 2024-07-16 AU AU2024204884A patent/AU2024204884A1/en active Pending
-
2025
- 2025-01-09 US US19/014,615 patent/US20250145698A1/en active Pending